$LPTX
LEAP THERAPEUTICS, INC.

2023 Q1 Form 10-K Financial Statement

#000110465923036239 Filed on March 24, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $3.784M $2.909M $11.80M
YoY Change 32.87% 4.15% 9.59%
% of Gross Profit
Research & Development $38.94M $11.03M $44.97M
YoY Change 400.28% 36.73% 39.82%
% of Gross Profit
Depreciation & Amortization $4.000K $4.000K $16.00K
YoY Change 0.0% -50.0% -44.83%
% of Gross Profit
Operating Expenses $42.73M $13.94M $56.76M
YoY Change 301.86% 28.35% 32.23%
Operating Profit -$42.73M -$56.76M
YoY Change 301.86% 37.02%
Interest Expense $591.0K $1.213M $54.00K
YoY Change 2714.29% 3467.65% 31.71%
% of Operating Profit
Other Income/Expense, Net $272.0K $775.0K $2.051M
YoY Change 635.14% -316.48% 67.29%
Pretax Income -$41.86M -$11.96M -$54.45M
YoY Change 303.46% 10.57% 34.07%
Income Tax $147.0K $147.0K
% Of Pretax Income
Net Earnings -$41.86M -$12.10M -$54.60M
YoY Change 303.46% 12.18% 34.52%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32 -$0.48
Diluted Earnings Per Share -$0.32 -$0.11 -$0.48
COMMON SHARES
Basic Shares Outstanding 118.8M 99.02M 113.2M
Diluted Shares Outstanding 129.3M 113.2M

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $102.0M $65.50M $65.50M
YoY Change -1.15% -43.0% -43.0%
Cash & Equivalents $102.0M $65.50M $65.50M
Short-Term Investments
Other Short-Term Assets $590.0K $351.0K $351.0K
YoY Change 20.16% -54.36% -54.36%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $104.7M $67.95M $67.95M
YoY Change -0.23% -41.86% -41.86%
LONG-TERM ASSETS
Property, Plant & Equipment $16.00K $20.00K $689.0K
YoY Change -50.0% -44.44% 39.19%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $15.00K $30.00K $1.714M
YoY Change -80.0% -66.67% 216.24%
Total Long-Term Assets $1.848M $2.403M $2.403M
YoY Change 93.1% 131.73% 131.73%
TOTAL ASSETS
Total Short-Term Assets $104.7M $67.95M $67.95M
Total Long-Term Assets $1.848M $2.403M $2.403M
Total Assets $106.5M $70.35M $70.35M
YoY Change 0.61% -40.33% -40.33%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.498M $5.657M $5.657M
YoY Change 28.25% 35.04% 35.04%
Accrued Expenses $4.388M $5.152M $5.568M
YoY Change 62.88% -3.99% -3.97%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $10.31M $11.23M $11.23M
YoY Change 40.4% 12.4% 12.4%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $192.0K $262.0K $262.0K
YoY Change 608.11% 608.11%
Total Long-Term Liabilities $192.0K $262.0K $262.0K
YoY Change 608.11% 608.11%
TOTAL LIABILITIES
Total Short-Term Liabilities $10.31M $11.23M $11.23M
Total Long-Term Liabilities $192.0K $262.0K $262.0K
Total Liabilities $10.50M $11.49M $11.49M
YoY Change 43.01% 14.59% 14.59%
SHAREHOLDERS EQUITY
Retained Earnings -$360.0M -$318.2M
YoY Change 31.42% 20.71%
Common Stock $119.0K $99.00K
YoY Change 35.23% 12.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $28.33M $58.87M $58.87M
YoY Change
Total Liabilities & Shareholders Equity $106.5M $70.35M $70.35M
YoY Change 0.61% -40.33% -40.33%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$41.86M -$12.10M -$54.60M
YoY Change 303.46% 12.18% 34.52%
Depreciation, Depletion And Amortization $4.000K $4.000K $16.00K
YoY Change 0.0% -50.0% -44.83%
Cash From Operating Activities -$12.70M -$13.01M -$49.04M
YoY Change 10.26% 21.44% 39.5%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $49.32M
YoY Change
Cash From Investing Activities $49.32M
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -29.00K 0.000 -210.0K
YoY Change -86.19% -100.0% -100.21%
NET CHANGE
Cash From Operating Activities -12.70M -13.01M -49.04M
Cash From Investing Activities 49.32M
Cash From Financing Activities -29.00K 0.000 -210.0K
Net Change In Cash 36.54M -13.01M -49.42M
YoY Change -412.4% 30.65% -178.63%
FREE CASH FLOW
Cash From Operating Activities -$12.70M -$13.01M -$49.04M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001509745
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85825283
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
59657742
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
88318454
CY2022 lptx Operating Lease Additional Liability
OperatingLeaseAdditionalLiability
609000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-54596000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-40587000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-37990
CY2022 dei Entity Registrant Name
EntityRegistrantName
LEAP THERAPEUTICS, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-4412575
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
47 Thorndike Street
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite B1-1
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Cambridge
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02141
CY2022 dei City Area Code
CityAreaCode
617
CY2022 dei Local Phone Number
LocalPhoneNumber
714-0360
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
CY2022 dei Trading Symbol
TradingSymbol
LPTX
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
93800000
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
118750386
CY2022 dei Auditor Firm
AuditorFirmId
274
CY2022 dei Auditor Name
AuditorName
EisnerAmper LLP
CY2022 dei Auditor Location
AuditorLocation
Iselin, New Jersey
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
114916000
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2021Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
1189000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
351000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
769000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
67950000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
116874000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
669000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
459000
CY2021Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
159000
CY2022Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
576000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
30000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
90000
CY2022Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
1108000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
293000
CY2022Q4 us-gaap Assets
Assets
70353000
CY2021Q4 us-gaap Assets
Assets
117911000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5657000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4189000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
416000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
432000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11225000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9987000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
262000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
37000
CY2022Q4 us-gaap Liabilities
Liabilities
11487000
CY2021Q4 us-gaap Liabilities
Liabilities
10024000
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
240000000
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
99021376
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
88318454
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
99000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
88000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
376807000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
371638000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
128000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-267000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318168000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-263572000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
70353000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
117911000
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1500000
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44965000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32160000
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11798000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10766000
CY2022 us-gaap Operating Expenses
OperatingExpenses
56763000
CY2021 us-gaap Operating Expenses
OperatingExpenses
42926000
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-56763000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-41426000
CY2022 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
925000
CY2021 lptx Investment Income Interest Expense
InvestmentIncomeInterestExpense
9000
CY2022 us-gaap Interest Expense
InterestExpense
54000
CY2021 us-gaap Interest Expense
InterestExpense
41000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
2051000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-608000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-379000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54449000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40611000
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
147000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54596000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40587000
CY2022 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.47
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
113239092
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
85825283
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85825283
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54596000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
395000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
312000
CY2022 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-54201000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40275000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
46651000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
993000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2021 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
6733000
CY2021 lptx Stock And Prefunded Warrants Issued During Period Value
StockAndPrefundedWarrantsIssuedDuringPeriodValue
96828000
CY2021 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
312000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3686000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
107887000
CY2022 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
395000
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5180000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54596000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
58866000
CY2022 us-gaap Profit Loss
ProfitLoss
-54596000
CY2021 us-gaap Profit Loss
ProfitLoss
-40587000
CY2022 us-gaap Depreciation
Depreciation
16000
CY2021 us-gaap Depreciation
Depreciation
29000
CY2021 lptx Amortization Of Contract Assets
AmortizationOfContractAssets
135000
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
399000
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
392000
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
5180000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
3686000
CY2022 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-608000
CY2021 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-379000
CY2021 lptx Fair Value Adjustment Of Restricted Stock Liability
FairValueAdjustmentOfRestrictedStockLiability
-204000
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-416000
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
639000
CY2022 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-152000
CY2021 us-gaap Increase Decrease In Deferred Income Taxes
IncreaseDecreaseInDeferredIncomeTaxes
-11000
CY2022 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
1009000
CY2021 lptx Increase Decrease In Research And Development Incentive Receivable
IncreaseDecreaseInResearchAndDevelopmentIncentiveReceivable
1159000
CY2021 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-209000
CY2022 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
945000
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3900000
CY2021 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1500000
CY2022 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-400000
CY2021 lptx Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-406000
CY2022 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
755000
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-597000
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-49044000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35157000
CY2021 lptx Proceeds From Issuance Of Common Stock September2021 Public Offering
ProceedsFromIssuanceOfCommonStockSeptember2021PublicOffering
97222000
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
993000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
210000
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
184000
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-210000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
98035000
CY2022 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-162000
CY2021 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-33000
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-49416000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
62845000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
52071000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
65500000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114916000
CY2022 lptx Deferred Costs In Accounts Payable And Accrued Expense Flame Merger
DeferredCostsInAccountsPayableAndAccruedExpenseFlameMerger
576000
CY2021 lptx Deferred Costs In Accounts Payable And Accrued Expense Public Offering
DeferredCostsInAccountsPayableAndAccruedExpensePublicOffering
210000
CY2022 lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
609000
CY2021 lptx Remeasurement Of Right Of Use Asset And Lease Liability
RemeasurementOfRightOfUseAssetAndLeaseLiability
323000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-318168000
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54596000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
65500000
CY2022Q4 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
50000000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The presentation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022 lptx Australian Research And Development Incentive Percent Expenses Reimbursed
AustralianResearchAndDevelopmentIncentivePercentExpensesReimbursed
0.435
CY2022Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
2099000
CY2021Q4 lptx Research And Development Incentive Receivable Current
ResearchAndDevelopmentIncentiveReceivableCurrent
1189000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
2051000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0310
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0082
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2020Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
73000
CY2021 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
1226000
CY2021 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
111000
CY2021 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
1000
CY2021Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
1189000
CY2022 lptx Cash Received For Research And Development Incentive
CashReceivedForResearchAndDevelopmentIncentive
1064000
CY2022 lptx Research And Development Incentive Income
ResearchAndDevelopmentIncentiveIncome
2051000
CY2022 lptx Research And Development Incentive Foreign Currency Translation Gain Loss
ResearchAndDevelopmentIncentiveForeignCurrencyTranslationGainLoss
-77000
CY2022Q4 lptx Research And Development Incentive Receivable
ResearchAndDevelopmentIncentiveReceivable
2099000
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;line-height:1.19;margin:0pt 0pt 10pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:18pt;margin:0pt 0pt 10pt 0pt;">Financial instruments which potentially subject the Company to credit risk consist principally of cash and cash equivalents. All cash and cash equivalents are held in United States or Australian financial institutions and money market funds. At times, the Company may maintain cash balances in excess of the federally insured amount of $250 per depositor, per insured bank, for each account ownership category. Although the Company currently believes that the financial institutions with whom it does business will be able to fulfill their commitments to the Company, there is no assurance that those institutions will be able to continue to do so. The Company has not experienced any credit losses associated with its balances in such accounts for the years ended December 31, 2022 and 2021.</p>
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y5M1D
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y9M25D
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2022Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
4644000
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
212000
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
80968000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
66241000
CY2022Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
576000
CY2021Q4 lptx Deferred Offering Costs Noncurrent
DeferredOfferingCostsNoncurrent
0
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2022Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62074000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
112726000
CY2022Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
62074000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
112726000
CY2022Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.08
CY2022 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
147000
CY2022 lptx Upfront Fees
UpfrontFees
3000000
CY2022Q4 us-gaap Deferred Policy Acquisition Costs
DeferredPolicyAcquisitionCosts
270000
CY2021 us-gaap Adjustment For Amortization
AdjustmentForAmortization
135000
CY2022 us-gaap Adjustment For Amortization
AdjustmentForAmortization
0
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
226000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
226000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
206000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
190000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
20000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2022 us-gaap Depreciation
Depreciation
16000
CY2021 us-gaap Depreciation
Depreciation
29000
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-24000
CY2022Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2093000
CY2021Q4 lptx Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
2499000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
533000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
181000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2526000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2686000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5152000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5366000
CY2022 lptx Operating Lease Additional Right Of Use Asset
OperatingLeaseAdditionalRightOfUseAsset
609000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
669000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
678000
CY2022 us-gaap Operating Lease Expense
OperatingLeaseExpense
451000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
423000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
452000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
267000
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
719000
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
41000
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
678000
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
49673390
CY2021Q4 lptx Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
1004000
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
297000
CY2022 lptx Number Of Vote On Common Shares
NumberOfVoteOnCommonShares
1
CY2022 us-gaap Dividends Common Stock
DividendsCommonStock
0
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6393853
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.29
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y11M15D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1961000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2482650
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.19
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2292
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.55
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
348593
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.17
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8525618
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.48
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y6M29D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7673000
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
4024900
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.50
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
633187
CY2022 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
2.17
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11917331
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.59
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y5M19D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
7543973
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.74
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M15D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
11917331
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.59
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y5M19D
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8270
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.6764
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5180000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3686000
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
210487000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-50325000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-39155000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-4124000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-1456000
CY2022 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-54449000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-40611000
CY2021 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
-37000
CY2021 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-37000
CY2022 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
147000
CY2021 us-gaap Deferred Foreign Income Tax Expense Benefit
DeferredForeignIncomeTaxExpenseBenefit
13000
CY2022 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
147000
CY2021 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
13000
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.060
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.072
CY2022 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.007
CY2021 us-gaap Effective Income Tax Rate Reconciliation Deductions
EffectiveIncomeTaxRateReconciliationDeductions
0.006
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.010
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.015
CY2022 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.003
CY2021 us-gaap Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential
EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
0.002
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.273
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.306
CY2022 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.020
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Reconciling Items Percent
EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent
0.001
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
44202000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
41207000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
12104000
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
11246000
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Foreign
DeferredTaxAssetsOperatingLossCarryforwardsForeign
98000
CY2022Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
9358000
CY2021Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
7172000
CY2022Q4 lptx Deferred Tax Assets Capitalized Research And Development Expenses
DeferredTaxAssetsCapitalizedResearchAndDevelopmentExpenses
9312000
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4757000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
4671000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
729000
CY2022Q4 lptx Deferred Tax Assets License Fees
DeferredTaxAssetsLicenseFees
840000
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
80968000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
66082000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
159000
CY2022 lptx Deferred Tax Expense Capitalized Research And Development
DeferredTaxExpenseCapitalizedResearchAndDevelopment
37873000000
CY2021 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-54596000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-40587000
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-54596000
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-40587000
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
113239092
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
85825283
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.47
CY2022 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants And Penny Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrantsAndPennyWarrants
14217716
CY2021 lptx Weighted Average Number Of Shares Outstanding Exercise Of Pre Funded Warrants And Penny Warrants
WeightedAverageNumberOfSharesOutstandingExerciseOfPreFundedWarrantsAndPennyWarrants
24930483
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
50958611
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
44916898
CY2022Q4 us-gaap Significant Supply Commitment Remaining Minimum Amount Committed
SignificantSupplyCommitmentRemainingMinimumAmountCommitted
4701000
CY2022 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
333000
CY2021 us-gaap Defined Contribution Plan Cost Recognized
DefinedContributionPlanCostRecognized
247000

Files In Submission

Name View Source Status
0001104659-23-036239-index-headers.html Edgar Link pending
0001104659-23-036239-index.html Edgar Link pending
0001104659-23-036239.txt Edgar Link pending
0001104659-23-036239-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lptx-20221231.xsd Edgar Link pending
lptx-20221231x10k.htm Edgar Link pending
lptx-20221231xex21d1.htm Edgar Link pending
lptx-20221231xex23d1.htm Edgar Link pending
lptx-20221231xex31d1.htm Edgar Link pending
lptx-20221231xex32d1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
lptx-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
lptx-20221231_lab.xml Edgar Link unprocessable
lptx-20221231_cal.xml Edgar Link unprocessable
lptx-20221231_pre.xml Edgar Link unprocessable
lptx-20221231x10k_htm.xml Edgar Link completed
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending